Bamco Inc. NY Takes $138,000 Position in Grail, Inc. (NASDAQ:GRAL)

Bamco Inc. NY bought a new position in shares of Grail, Inc. (NASDAQ:GRAL) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,713 shares of the company’s stock, valued at approximately $138,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Crcm LP purchased a new position in shares of Grail during the 4th quarter valued at $65,061,000. Primecap Management Co. CA bought a new stake in Grail during the fourth quarter valued at $37,118,000. Vanguard Group Inc. purchased a new position in Grail during the fourth quarter worth about $25,902,000. AQR Capital Management LLC bought a new position in Grail in the 4th quarter worth about $14,828,000. Finally, Arbiter Partners Capital Management LLC purchased a new stake in shares of Grail in the 4th quarter valued at about $14,827,000.

Grail Price Performance

Shares of NASDAQ GRAL opened at $34.26 on Tuesday. The stock’s 50-day moving average is $29.89 and its 200 day moving average is $25.29. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99.

Grail (NASDAQ:GRAL) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.41) by $2.55. The business had revenue of $38.25 million during the quarter, compared to analysts’ expectations of $35.33 million. Equities research analysts expect that Grail, Inc. will post -15.15 earnings per share for the current year.

Insider Buying and Selling at Grail

In other news, CFO Aaron Freidin sold 1,816 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the transaction, the chief financial officer now owns 335,170 shares in the company, valued at approximately $10,457,304. This trade represents a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Ragusa sold 7,625 shares of the business’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.21, for a total transaction of $237,976.25. Following the completion of the transaction, the chief executive officer now owns 828,662 shares in the company, valued at $25,862,541.02. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 146,735 shares of company stock worth $4,947,263 over the last three months.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Canaccord Genuity Group initiated coverage on shares of Grail in a research report on Monday, April 21st. They issued a “buy” rating and a $32.00 price objective on the stock. Morgan Stanley increased their price target on shares of Grail from $16.00 to $20.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 18th.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.